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Intensification of Anemia by Secondary 
Hyperparathyroidism in Hemodialysis Patients 
 
 
 
Abstract 
The excessive amounts of parathyroid hormone in secondary hyper-
parathyroidism (SHPTH) is suggested to interfere with normal 
erythropoiesis.  In SHPTH, during chronic renal failure, due to the 
impairment of erythropoietin synthesis, this effect is more pro-
nounced.  In the present study the role of secondary hyperparathy-
roidism in the severity of anemia was evaluated in hemodialysis pa-
tients (n=36; 16 females and 20 males) with the end-stage renal fail-
ure.  CBC, Hgb, Hct, calcium, phosphorus, alkaline phosphatase, 
intact parathyroid hormone (iPTH), serum iron, total iron binding 
capacity, transferin saturation, ferritin as well as dialysis adequacy 
were measured.  Partial correlation test was performed for analysis 
of the data making adjustments for age, duration of hemodialysis and 
ferritin levels.  The mean±SD for iPTH, Hgb and Hct were 439.4 ± 
433 pg/ml, 9 ± 1.9 and 28.8 ± 6.3 respectively.  The mean duration 
of hemodialysis for the patients was 25.1 ± 24 months.  A reverse 
correlation was found between iPTH and Hct and Hgb as well as 
between alkaline phosphatase and Hgb and Hct (0<0.05).  It was 
shown that severity of hyperparathyroidism correlated with severe of 
anemia.  It is concluded that secondary hyperparathyroidism per se 
can intensify anemia in hemodialysis patients.  A more efficient con-
trol of hyperphosphatemia and parathormone hypersecretion is thus 
needed to achieve a better management of anemia in hemodialysis 
patients.  
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Introduction 
 
nemia is commonly one of the leading causes of increased 
cardiovascular morbidity and mortality in patients with chronic 
renal failure (CRF).  In this study we evaluated the role of 
secondary hyperparathyroidism in severity of anemia in hemodialysis 
patients.  The present investigation is performed on 36 patients (16 
females and 20 males of whom 23 were over 40 years old), with end 
stage renal failure and undergoing regular hemodialysis.  Serum cal-
cium, phosphorus, alkakine phosphatase (ALP), Hgb, Hct, urea re-
duction rate and serum iron, total iron binding capacity, ferritin, trans-
ferin as well as intact PTH (iPTH) were measured.  None of the pa-
tients received ACE-inhibitors, NSAIDS and none had external blood 
loss or ADPKD.  At the end of each dialysis session all the patients 
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Table 1: Minimum, maximum and mean±SD of some of the data 
Vabiable Unit Minimum Maximum Mean±SD 
Hemoglobin mg/dl 6 14.5 9 ± 1.9 
Hematocrit % 20 52 28.8 ± 6.3 
Ferritin ng/ml 94 1000 183 ± 4.2 
Transferrin Saturation % 22 100 45.5 ± 18 
Urea Reduction Rate % 49 77 59.5 ± 6.1 
Phosphate mg/dl 3 12 6.6 ± 2.3 
Intact Parathyroid Hormone (iPTH) pg/ml 25 2234 439.4 ± 433.6 
Alkakine Phosphatase (ALP) Iu/L 100 1280 385 ± 227 
Calcium x Phosphate --- 30 95 54 ± 16 
 
received an intravenous dose of Eprex 2000U.  
Descriptive data stratified as mean±SD and partial 
correlation test was used for adjustment of age, 
ferritin levels and duration of hemodialysis.  The 
mean duration of hemodialysis was 25.1±24 
months.  The number of hemodialysis sessions 
were 3, 2 and once per week for 58, 39, and 3 per-
cent of patients respectively.  The mean±SD, mini-
mum and maximum values of our data are pre-
sented in Table 1.  We found a reverse correlation 
(Fig. 1) between serum iPTH and Hgb (r=-0.302, 
p=0.044) and between ALP and Hgb (r=-0.343, 
p=0.025) as shown in Fig.2.  Also a reverse corre-
lation between iPTH and Hct (r=-0.428) and be-
tween ALP and Hct (r=-0.309) were observed 
(p<0.05). 
The reverse correlation found between iPTH 
and Hct and Hgb as well as between ALP and Hct 
and Hgb levels, signify secondary hyperparathy-
roidism(SHPTH) in hemodialysis patients.  These, 
among other factors, contribute to the severity of 
anemia in these patients.  Trovato, et al1 in their 
studies on 45 hemodialysis patients showed a re-
verse correlation between high degree of anemia 
and hyperparathyroidism and also a higher re-
quirement of patients with elevated iPTH for re-
combinant human erythropoietin (r-HuEpo).  Neves 
et al.2 studying a total of 86 elderly patients with 
hyperparathyroidism showed that they had lower 
Hct and Hgb levels compared to younger patients 
on a similar dose of erythropoietin (Epo).  Other 
studies have shown beneficial effect of parathyroi-
dectomy (PTX) on anemia in hemodialysis patients 
undergoing treatment for SHPTH.3,4  Yasunga et al, 
showed a significant increase of hemoglobin level 
from three months after PTX, that was associated 
with a consistent increase in reticulocyte count5.  
Also Fugita et al, reporting on 13 parathyroidec-
tomized hemodialysis patients found a 10% in-
crease in RBC mass after PTX6.  Moreover, in the 
 
Figure 1: Reverse correlation of iPTH with Hgb 
(r=-0.520, p=0.001) 
 
Figure 2: Reverse correlation of ALP with Hgb 
(r=-0.382, p=0.001) 
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studies of Grutzmacher7and Podjamy8 a significant 
increment of Hct was observed following PTX.  One 
of the features of renal osteodystrophy is its refrac-
toriness to treatment with r-HuEpo which can be 
observed in severe HPTH.  In fact, poor response 
to r-HuEpo in the presence of very high levels of 
PTH (>500-1000 pg/ml) should prompt radiographic 
evaluation of the skeleton for SPTH-related osteitis 
fibrosa.  A variety of pathophysiologic mechanisms 
have been postulated for the contribution of hyper-
parathyroidism to both anemia and r-HuEpo resis-
tance.  In the pre-r-HuEpo era, these centered on a 
direct toxic effect of PTH on proliferation of red cell 
precursors in the marrow and antagonism of the 
effect of endogeneous or exogenous Epo.  It is 
postulated that calcitrol deficiency, direct effect of 
PTH on Epo release, red blood cell production and 
loss of erythrocytes, reduce erythropoiesis.  Stud-
ies of these mechanisms have produced disparate 
results possibly because SHPTH may have only a 
relatively minor role in anemia that may be masked 
by confounding effects of other factors with greater 
impact.  More recent studies have focused on the 
physical effects of high turnover bone disease on 
the size of erythron.  In the r-HuEpo-treated pa-
tients, a clear relationship has been demonstrated 
between the degree of trabecular fibrosis and r-
HuEpo dose.  Moreover, the high PTH level could 
also shift bone cells towards adipocytes.  It is sug-
gested that excessive amounts of PTH interferes 
with normal erythropoiesis by down-regulating the 
erythropoietin receptors on erythroid progenitor 
cells in the bone marrow.  Therefore, physiologic 
concentrations of Epo can no longer sustain normal 
red cell counts with ensuing normocytic normo-
chromic anemia.  In primary hyperparathyroidism 
this effect is observed with very high concentrations 
of PTH.  In SHPTH during chronic renal failure, this 
effect is more pronounced because Epo synthesis 
is impaired. attaiing an acceptable Hgb and Hct 
levels and treatment of SHPTH are two major con-
cerns in hemodialysis centers.  Moreover, poor 
compliance with phosphorus restricted diets, lack of 
cooperation with regard to using phosphate bind-
ers, inadequate hemodialysis, low socio-economic 
state of some patients and unavailability of newer 
phosphate binders such as Rena-jel and the drugs 
decreasing PTH hypersecretion, are problems in-
volved in SHPTH management.  Thus, more atten-
tion is required to control hyperphosphatemia and 
PTH hypersecretion with newer drugs which sup-
press many debilitating side effects of SHPTH, re-
quired for the improvement of anemia.  
 
References 
 
1 Trovato GM, Carpinteri G, Spina S, et al: Hy-
perparathyroidism, anemia and erythropoietin: 
effects on systolic fuction of dialysis patients. 
Abstracts of XXXIth congress of European Re-
nal Association European Dialysis ND Tras-
plantation association. September 5-8, Madrid 
in Nephrol Dial Transpl 1999;14: A190.  
2 Neves PL, Trivino J, Casaubon F, et al: Elderly 
patients on chronic hemodialysis: effect of sec-
ondary hyperparathyroidism on the hemoglobin 
level. Int Urol Nephrol 2002; 34(1):147-9 . 
3 Gallieni M, Corsi C, Brancaccio D: Hyperpara-
thyroidism and anemia in renal failure. Am J  
Nephrol 2000;20(2):89-96.  
4 Sikole A: Pathogenesis of anemia in hyper-
parathyroidism. Med hypotheses 2000;54(2): 
236-8.  
5 Yasunaga C, Matsuo K, Yanagida T, et al: 
Early effects of parathyroidectomy on erthro-
poietin production in secondary hyperparathy-
roidism. Am J Surg 2002;183(2):199 – 204 . 
6 Fujita Y, Horiguchi S, kuki A: Excessive level of 
parathyroid hormone may induce the reduction 
of recombinant human erythropoietin effect on 
renal anemia. Miner Electrolyte Metab 1995;  
21(1-3): 50-4 . 
7 Grutzmacher P, Radtke HW, Fassbinder W, et 
al:  Effect of secondary hyperparathyroidism on 
the anemia of end-stage renal failure: in vivo 
and vitro studies. Proc Eur Dial Transplant 
Assoc 1983;20:739-45 . 
8 Podjarny E, Rathaus M, Korts Z, et al: Is ane-
mia of chronic renal failure related to secon-
dary hyperparathyroidism? Arch Intern Med 
1981;141(4): 453-5.   
  
 
